Know Your Recurrence Risk
Helping Patients Around the Globe!!
Personalized Cancer Treatment with CanAssist Breast Test
-
Personalized treatment through risk prediction
-
Detect low-risk patients for the avoidance of chemotherapy
-
Minimize chemotherapy side effects
Up to 3 out of 4 early-stage, hormone receptor-positive breast cancer patients may not benefit from chemotherapy. Therefore, it is necessary to detect patients who are at low risk of recurrence to avoid overtreatment with chemotherapy, given its side effects and the toll it takes on the patient’s quality of life. This makes accurate risk prediction an all-important prerequisite for effective treatment.
If you have been recently diagnosed with early-stage invasive breast cancer, there is a possibility that you may not require chemotherapy. Along with the existing pathology report, the CanAssist Breast test result lets you know the likelihood of cancer returning at another organ and whether you are likely to benefit from chemotherapy or not. Knowing the patient's recurrence risk allows doctors to devise treatment plans that are in tune with the prognosis, thereby maintaining an optimal balance between the benefits and side effects. CanAssist Breast makes customized treatment possible while keeping the costs down in low-risk cases.